MetaCap

Harrow Inc. (HROW)

NASDAQ: HROWHealth CareBiotechnology: Pharmaceutical PreparationsUSD

30.41-1.72 (-5.35%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HROW stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.76
52-week range
25.76 – 54.85
Day range
30.32 – 32.43
Volume / Avg
911.03K / 626.20K
Beta
—

52-week range

$25.76$54.85

HROW stock today

Shares of Harrow (HROW) finished lower on Nov 20 at $30.41, a drop of 5.35% or $1.72 per share, versus the S&P 500's 3.70% decline. At this level, HROW sits near the bottom of its 52-week range of $25.76 to $54.85: 44.6% below the high, set on Jan 7, 2026 and 18.1% above the low. HROW is down 37.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.8%.

Harrow has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Harrow

Company profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Mark L. Baum J.D.
Headquarters
Nashville, TN
Employees
373
Website
harrow.com

Financial highlights

Full financials

In fiscal 2025, Harrow generated $272.3 million in revenue, up 36.4% from fiscal 2024, its 5th consecutive year of revenue growth. Harrow reported a net loss of $5.1 million, compared with a loss of $17.5 million a year earlier. Gross margin was 75.1% (down from 75.3%) and operating margin 11.2%.

Harrow annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$272.30M$199.61M$130.19M$88.59M$72.48M
Growth+36.41%+53.32%+46.95%+22.24%+48.30%
Net income$-5.14M$-17.48M$-24.41M$-14.09M$-18.01M
EPS (diluted)$-0.14$-0.49$-0.75$-0.51$-0.69

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$62.25+104.70%

  • Strong buy 0
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $42.00High $88.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$0.25 vs $0.13
Surprise
+92.31%

HROW news

All HROW news

Harrow peers

Health Care sector
HROW peer companies
CompanyPrice% ChgMarket capCompare
CMPSCOMPASS Pathways Plc American Depository Shares8.05-6.94%$1.14Bvs HROW
GPCRStructure Therapeutics Inc. ADR16.13-5.78%$1.15Bvs HROW
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs HROW
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs HROW
KARDKardigan Inc.11.54-7.83%$1.08Bvs HROW
GHRSGH Research PLC17.53-5.55%$1.20Bvs HROW
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs HROW
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs HROW

Indexes, lists and sector

Harrow stock FAQ

What is Harrow's stock price today?

HROW last traded at $30.41 as of Nov 20, 4:00 PM EST, down 5.35% on the day. Prices are delayed at least 15 minutes.

Does Harrow pay a dividend?

No. Harrow does not currently pay a regular cash dividend.

Who is Harrow's CEO?

Mr. Mark L. Baum J.D. is the chief executive officer of Harrow Inc., which has about 373 employees.

Has HROW ever split its stock?

Yes. The most recent HROW stock split was a 1-for-5 split on Feb 8, 2013, one of 2 splits on record.

What is the HROW 52-week high?

The 52-week high for HROW is $54.85 and the 52-week low is $25.76. The stock is currently 44.6% below its high.

Compare HROW